Research report explores the Constipation Treatment Market

Publisher: The Insight Partners

According to our new market research study on “Constipation Treatment Market to 2027 – Global Analysis and Forecast – by Therapeutic, Disease, and Distribution Channel,” the market is expected to reach US$ 13,386.19 million by 2027 from US$ 8,533.89 million in 2019; it is estimated to grow at a CAGR of 5.9% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth. The key factors driving the market growth include the rising prevalence of chronic constipation and increasing number of FDA approvals and drug developments drive the market growth. However, preference for home and herbal remedies hinder the market growth.

Based on therapeutic, the constipation treatment market is segmented into laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C agonists, and 5-HT4 receptor agonists. The laxatives segment held the largest share of the market in 2019. However, GC-C agonists segment is anticipated to register the highest in the market during the forecast period. The growth of GC-C agonists is expected to grow at fastest growth rate due to rising product developments and product launches in the market.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.theinsightpartners.com/sample/TIPRE00005408/

AbbVie's Inc.; Takeda Pharmaceutical Company Limited; Bausch Health Companies Inc.; Bayer AG; Mallinckrodt Plc; Abbott; Cosmo Pharma; Sanofi; Albireo Pharma, Inc, and AstraZeneca are among the leading companies operating in the constipation treatment market. These companies adopt various organic and inorganic growth strategies to expand their global footprints and product portfolios, to meet the rising demand for the constipation treatments and related services. For instance, in July 2020, AbbVie Inc. has a product, MD-7246 a drug to treat constipation associated with irritable bowel syndrome in phase II clinical trial. The drug is formulated to treat constipation in adults, which is expected to serve people and help them in improving their bowel conditions.

By Therapeutic

• Laxatives
• Chloride Channel Activators
• Peripherally Acting Mu-Opioid Receptor Antagonists
• GC-C Agonists
• 5-HT4 Receptor Agonists

By Disease

• Chronic Idiopathic Constipation
• Irritable Bowel Syndrome With Constipation
• Opioid-Induced Constipation

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
• South and Central America (SCAM)
  • Brazil
  • Argentina

Company Profiles

• AbbVie's Inc
• Takeda Pharmaceutical Company Limited
• Bausch Health Companies Inc.
• Bayer AG
• Mallinckrodt Plc
• Abbott
• Cosmo Pharma
• Sanofi
• Albireo Pharma, Inc,
• AstraZeneca

Purchase a copy of this research report @ https://www.theinsightpartners.com/buy/TIPRE00005408/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com